Reduction of Long-Term Opioid Prescribing for Back Pain in Community Health Centers After a Medicaid Policy Change

References

1. 1.↵
   1. Jalal H,
   2. Buchanich JM,
   3. Roberts MS,
   4. Balmert LC,
   5. Zhang K,
   6. Burke DS

   . Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016. Science 2018;361.
2. 2.↵
   1. Von Korff MR,
   2. Franklin G

   . Responding to America's iatrogenic epidemic of prescription opioid addiction and overdose. Med Care 2016;54:426–9.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Alpert AE,
   2. Evans WN,
   3. Lieber EMJ,
   4. Powell D

   . Origins of the opioid crisis and its enduring impacts. National Bureau of Economic Research Working Paper Series. 2019;No. 26500.
4. 4.↵
   1. Levy B,
   2. Paulozzi L,
   3. Mack KA,
   4. Jones CM

   . Trends in opioid analgesic-prescribing rates by specialty, U.S., 2007-2012. Am J Prev Med 2015;49:409–13.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Olsen Y,
   2. Daumit GL,
   3. Ford DE

   . Opioid prescriptions by U.S. primary care physicians from 1992 to 2001. The journal of pain: official journal of the American Pain Society 2006;7:225–35.

   OpenUrl
6. 6.↵
   Centers for Disease Control and Prevention. 2019 Annual surveillance report of drug-related risks and outcomes - United States. Surveillance Special Report. 2019. Published November 1, 2019. Accessed December 30, 2019.
7. 7.↵
   1. Beaudoin FL,
   2. Banerjee GN,
   3. Mello MJ

   . State-level and system-level opioid prescribing policies: the impact on provider practices and overdose deaths, a systematic review. J Opioid Manag 2016;12:109–18.

   OpenUrlPubMed
8. 8.↵
   Office of National Drug Control Policy. National drug control strategy. 2011. https://obamawhitehouse.archives.gov/sites/default/files/ondcp/ndcs2011.pdf. Accessed January 23, 2020.
9. 9.↵
   1. Dowell D,
   2. Haegerich TM,
   3. Chou R

   . CDC Guideline for prescribing opioids for chronic pain–United States, 2016. JAMA 2016;315:1624–45.

   OpenUrlCrossRefPubMed
10. 10.↵
    Oregon Health Authority Health Evidence Review Commission. Coverage guidance: lower back pain: non-pharmacological/non-invasive interventions. https://www.oregon.gov/oha/HPA/DSI-HERC/EvidenceBasedReports/Low-Back-Pain-Non-Pharmacologic-Non-Invasive-Interventions-11-13-14.pdf.Published2014. Accessed November 22, 2020.
11. 11.↵
    Oregon Health Authority Health Evidence Review Commission. Coverage guidance: lower back pain: pharmacological interventions. https://www.oregon.gov/oha/HPA/DSI-HERC/EvidenceBasedReports/Low-Back-Pain-Pharmacologic-Interventions-Final-11-13-14.pdf.Published2014. Accessed November 22, 2020.
12. 12.↵
    1. Eaves ER,
    2. Hsu CW,
    3. DeBar LL,
    4. et al

    . Whole systems within whole systems: the Oregon health plan's expansion of services for back and neck pain. J Altern Complement Med 2019;25:S61–S68.

    OpenUrl
13. 13.↵
    Oregon Health Evidence Review Commission. Prioritized list archives. https://www.oregon.gov/oha/HPA/DSI-HERC/Pages/Prioritized-List-Archives.aspx. Accessed March 7, 2021.
14. 14.↵
    1. Kuntz JL,
    2. Dickerson JF,
    3. Schneider JL,
    4. et al

    . Factors associated with opioid-tapering success: A mixed methods study. J Am Pharm Assoc (2003) 2021;60:248–57.

    OpenUrl
15. 15.↵
    1. Von Korff M,
    2. Dublin S,
    3. Walker RL,
    4. et al

    . The impact of opioid risk reduction initiatives on high-dose opioid prescribing for patients on chronic opioid therapy. J Pain 2016;17:101–10.

    OpenUrl
16. 16.↵
    1. Darnall BD,
    2. Juurlink D,
    3. Kerns RD,
    4. et al

    . International stakeholder community of pain experts and leaders call for an urgent action on forced opioid tapering. Pain Med 2019;20:429–33.

    OpenUrl
17. 17.↵
    1. Kertesz SG

    . Outcomes after opioid dose reductions and stoppage: it's time to start counting. J Subst Abuse Treat 2019;103:64–5.

    OpenUrl
18. 18.↵
    1. Dowell D,
    2. Haegerich T,
    3. Chou R

    . No shortcuts to safer opioid prescribing. N Engl J Med 2019;380:2285–7.

    OpenUrlPubMed
19. 19.↵
    U.S. Department of Health and Human Services. HHS guide for clinicians on the appropriate dosage reduction or discontinuation of long-term opioid analgesics. https://www.cms.gov/About-CMS/Story-Page/CDCs-Tapering-Guidance.pdf. Published 2019. AS12,2.
20. 20.↵
    Centers for Disease Control and Prevention. Pocket guide: tapering opioids for chronic pain. https://www.cdc.gov/drugoverdose/pdf/clinical_pocket_guide_tapering-a.pdf.
21. 21.↵
    National Association of Community Health Centers. Community health center chartbook 2019. http://www.nachc.org/wp-content/uploads/2019/01/Community-Health-Center-Chartbook-FINAL-1.28.19.pdf.
22. 22.↵
    U.S. National Library of Medicine - ClinicalTrials.gov. A Naturalistic Experiment Evaluating the Impact of Medicaid Treatment Reimbursement Changes on Opioid Prescribing and Patient Outcomes Among Patients With Back Pain (Back on Track). https://clinicaltrials.gov/ct2/show/NCT03393143.
23. 23.↵
    1. Charlson ME,
    2. Charlson RE,
    3. Peterson JC,
    4. Marinopoulos SS,
    5. Briggs WM,
    6. Hollenberg JP

    . The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol 2008;61:1234–40.

    OpenUrlCrossRefPubMedWeb of Science
24. 24.↵
    1. Mayhew M,
    2. DeBar LL,
    3. Deyo RA,
    4. et al

    . Development and assessment of a crosswalk between ICD-9-CM and ICD-10-CM to identify patients with common pain conditions. J Pain 2019;20:1429–45.

    OpenUrlPubMed
25. 25.↵
    Centers for Disease Control and Prevention. Data resources - oral MMEs. 2018. https://www.cdc.gov/drugoverdose/resources/data.html.
26. 26.↵
    1. Wen H,
    2. Schackman BR,
    3. Aden B,
    4. Bao Y

    . States with prescription drug monitoring mandates saw a reduction in opioids prescribed to Medicaid enrollees. Health Aff (Millwood) 2017;36:733–41.

    OpenUrlAbstract/FREE Full Text
27. 27.↵
    1. Mauri AI,
    2. Townsend TN,
    3. Haffajee RL

    . The Association of State Opioid Misuse Prevention Policies with patient- and provider-related outcomes: a scoping review. Milbank Q 2020;98:57–105.

    OpenUrl
28. 28.↵
    1. Muench J,
    2. Fankhauser K,
    3. Voss RW,
    4. et al

    . Assessment of opioid prescribing patterns in a large network of US community health centers, 2009 to 2018. JAMA Netw Open 2020;3:e2013431.

    OpenUrl
29. 29.↵
    1. Hartung DM,
    2. Kim H,
    3. Ahmed SM,
    4. et al

    . Effect of a high dosage opioid prior authorization policy on prescription opioid use, misuse, and overdose outcomes. Subst Abus 2018;39:239–46.

    OpenUrl
30. 30.↵
    Oregon Health Authority Office of Delivery Systems Innovation. Statewide Performance Improvement Project. https://www.oregon.gov/oha/HPA/DSI/pages/Performance-Improvement-Project.aspx. Published 2019. AS12,2.
31. 31.↵
    1. Harden P,
    2. Ahmed S,
    3. Ang K,
    4. Wiedemer N

    . Clinical Implications of Tapering Chronic Opioids in a Veteran Population. Pain Med 2015;16:1975–81.

    OpenUrl
32. 32.↵
    1. Weimer MB,
    2. Hartung DM,
    3. Ahmed S,
    4. Nicolaidis C

    . A chronic opioid therapy dose reduction policy in primary care. Subst Abus 2016;37:141–7.

    OpenUrlCrossRefPubMed
33. 33.↵
    1. Fenton JJ,
    2. Agnoli AL,
    3. Xing G,
    4. et al

    . Trends and rapidity of dose tapering among patients prescribed long-term opioid therapy, 2008-2017. JAMA Netw Open 2019;2:e1916271.

    OpenUrlCrossRefPubMed
34. 34.↵
    1. Mark TL,
    2. Parish W

    . Opioid medication discontinuation and risk of adverse opioid-related health care events. J Subst Abuse Treat 2019;103:58–63.

    OpenUrlCrossRefPubMed
35. 35.↵
    1. Ranapurwala SI,
    2. Ringwalt CL,
    3. Pence BW,
    4. et al

    . State medical board policy and opioid prescribing: a controlled interrupted time series. Am J Prev Med 2020;60:343–51.

    OpenUrl
36. 36.↵
    1. Buonora M,
    2. Perez HR,
    3. Heo M,
    4. Cunningham CO,
    5. Starrels JL

    . Race and gender are associated with opioid dose reduction among patients on chronic opioid therapy. Pain medicine 2019;20:1519–27.

    OpenUrl
37. 37.↵
    1. Pletcher MJ,
    2. Kertesz SG,
    3. Kohn MA,
    4. Gonzales R

    . Trends in opioid prescribing by race/ethnicity for patients seeking care in US emergency departments. JAMA 2008;299:70–8.

    OpenUrlCrossRefPubMedWeb of Science
38. 38.↵
    1. Singhal A,
    2. Tien YY,
    3. Hsia RY

    . Racial-ethnic disparities in opioid prescriptions at emergency department visits for conditions commonly associated with prescription drug abuse. PLoS One 2016;11:e0159224.

    OpenUrlCrossRefPubMed
39. 39.↵
    1. Chou R,
    2. Ballantyne JC,
    3. Fanciullo GJ,
    4. Fine PG,
    5. Miaskowski C

    . Research gaps on use of opioids for chronic noncancer pain: findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain 2009;10:147–59.

    OpenUrlCrossRefPubMedWeb of Science